Opexa Therapeutics Inc  

(Public, NASDAQ:OPXA)   Watch this stock  
Find more results for OPXA
1.56
+0.03 (1.96%)
Aug 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.51 - 1.59
52 week 1.25 - 3.70
Open 1.51
Vol / Avg. 107,635.00/120,487.00
Mkt cap 43.15M
P/E     -
Div/yield     -
EPS -1.06
Shares 27.66M
Beta 2.71
Inst. own 6%
May 14, 2014
Q1 2014 OPEXA THERAPEUTICS INC Earnings Conference Call
May 14, 2014
Q1 2014 OPEXA THERAPEUTICS INC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -1047.92% -1315.03%
Operating margin -1049.41% -1140.20%
EBITD margin - -914.67%
Return on average assets -59.94% -109.63%
Return on average equity -77.31% -141.99%
Employees 38 -
CDP Score - -

Address

2635 Technology Forest Blvd.
THE WOODLANDS, TX 77381
United States - Map
+1-281-7750600 (Phone)
+1-281-8728585 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company�s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tcelna is a T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with secondary progressive MS (SPMS).Tcelna is a personalized therapy that is specifically tailored to each patient�s disease profile. The TERMS study was a multi-center, randomized, double blind, placebo-controlled trial in 150 patients with RRMS or high risk Clinically Isolated Syndrome.

Officers and directors

Neil K. Warma President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Karthik Radhakrishnan CFA Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Don G. Healey Ph.D. Chief Scientific Officer
Bio & Compensation  - Reuters
Donna R. Rill Chief Development Officer
Age: 59
Bio & Compensation  - Reuters
Timothy C. Barabe Director
Age: 61
Bio & Compensation  - Reuters
Hans-Peter Hartung M.D., Ph.D. Director
Bio & Compensation  - Reuters
Gail J. Maderis Independent Director
Age: 55
Bio & Compensation  - Reuters
Michael S. Richman Independent Director
Age: 52
Bio & Compensation  - Reuters
Scott B. Seaman CPA Independent Director
Age: 57
Bio & Compensation  - Reuters